MA-SHERLOCK-BIOSCIENCES
23.6.2021 14:32:06 CEST | Business Wire | Press release
The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that its partnerships will increase COVID-19 diagnostic manufacturing capacity by up to 10 million tests per month by year-end. Through multiple license agreements this year with organizations including ALBOT Technologies , Cooper International , LogicInk , Rokline , United PPE and binx health , The 221b Foundation has enabled manufacturing and global distribution in the U.S., United Arab Emirates, India and Singapore, and is in discussions to expand beyond these geographies to increase access for vital diagnostic solutions around the world.
The 221b Foundation was founded to aid in the fight against the global COVID-19 pandemic by enabling access to intellectual property associated with the company’s SHERLOCK™ CRISPR-based technology. Proceeds from third-party sales of SHERLOCK CRISPR COVID-19 products have supported programs that promote racial and gender diversity in STEM, including HMS MEDscience , Scratch and The Akilah Institute .
“As the world mobilized to respond to the COVID-19 pandemic, our mission obligated us to be part of the global solution. The 221b Foundation is one of our most important responses – an open innovation model to provide our comprehensive CRISPR IP estate to expedite the end of the pandemic,” said Rahul Dhanda, co-founder, president and CEO of Sherlock Biosciences. “Since launching the Foundation, we have enabled a variety of use cases from point-of-care to strategic testing centers in the country of Nepal to highly automated clinical environments. We are honored to be meeting this global need while creating pathways for programs that support gender and racial diversity in STEM, a vital step to ensure our industry reflects the communities it serves around the world.”
Since receiving Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration in May 2020 for its Sherlock™ CRISPR SARS-CoV-2 kit – the first FDA-authorized use of CRISPR technology – The 221b Foundation has continued to increase access to the technology through partnerships around the world.
“Since launching The 221b Foundation, we have continued to advance the platform workflow to provide a high-throughput, low cost and incredibly accurate solution to patients worldwide, while advancing the field of CRISPR diagnostics with innovations building on our discovery of new Cas enzymes to enable fully integrated, real-time multiplex testing,” said William J. Blake, Ph.D., Chief Technology Officer, Sherlock Biosciences. “Our and our partners’ assays are highly effective at detecting new, highly transmissible COVID-19 variants, making them a powerful solution to this global public health crisis.”
To learn more about licensing opportunities or our CRISPR SARS-CoV-2 method, contact us directly at sales@sherlock.bio or read our White Paper here .
About The 221b Foundation
The 221b Foundation was founded with the dual mission to assist in the eradication of COVID-19, while supporting racial and gender diversity in STEM. By providing support and intellectual property that enables both non-profit and for-profit entities to develop CRISPR-based diagnostic testing, The 221b Foundation seeks to aid in the fight against the global COVID-19 pandemic while furthering access and diversity in STEM industries. Led by industry experts in the fields of diagnostic testing, STEM and diversity, The 221b Foundation envisions a world where advances in CRISPR technology fuel the innovations that will put an end to the COVID-19 pandemic. For more information, please visit: 221bfoundation.org
.
About Sherlock Biosciences
Sherlock Biosciences is dedicated to providing global access to the simplest and most accurate tests that empower individuals to control their own healthcare. Through its Engineering Biology platforms, the company is developing applications of SHERLOCK™, a CRISPR-based method for “smart amplicon detection,” and INSPECTR™, a synthetic biology-based molecular diagnostics platform that is instrument-free. SHERLOCK and INSPECTR can be used in virtually any setting without complex instrumentation, opening up a wide range of potential applications in areas including precision oncology, infection identification, food safety, at-home tests and disease detection in the field. In 2020, the company made history with the first FDA-authorized use of CRISPR technology. For more information visit Sherlock.bio
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005110/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
illumynt Appoints Anthony Giannetti as Senior Vice President of Global Operations16.7.2026 13:00:00 CEST | Press release
Seasoned operations leader brings two decades of OEM and ITAD experience, including Dell, Apple, and Microsoft, as illumynt scales its global AI hardware lifecycle platform illumynt, a technology-driven leader in AI hardware lifecycle recovery and IT asset disposition (ITAD), today announced that Anthony "Tony" Giannetti has joined the company as Senior Vice President of Global Operations, effective July 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716696044/en/ Anthony Giannetti, SVP Global Operations Giannetti brings more than two decades of operations and supply chain leadership from some of the technology industry's largest OEMs, including Dell, where he managed reverse supply chain operations, and Apple and Microsoft, where he held additional operations leadership roles. His background spans production engineering, reverse logistics, and large-scale operational management, disciplines directly relevant to
Compvide™ Announces Strategic Collaboration with OpZira™ to Accelerate Growth and Advance the CIMED™ Platform16.7.2026 12:47:00 CEST | Press release
Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform. Through the collaboration, OpZira will provide comprehensive operational support across clinical, customer care, finance, manufacturing, marketing, quality, and regulatory functions,” stated Clark Tedford, Ph.D., President and CEO, OpZira, Inc. “By leveraging OpZira’s established operational infrastructure and expertise, Compvide can remain focused on advancing its scientific innovation while expanding its capabilities in complement-focused diagnostics and translational medicine.” “Partnering with an experienced organization that understands the unique needs of emerging healthcare companies is an important step for Compvide as we continue building the company,” said Sadam Yaseen
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy16.7.2026 12:35:00 CEST | Press release
Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapyFindings published in the Journal of Psychopharmacology Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment administration sessions showed minimal interaction. Monitoring and support were linked by patients to presence, availability, reassurance and validation. The limited and non-directive nature of these interactions distinguishes this fo
Circus Commences Operations with Ukrainian Ground Forces16.7.2026 12:04:00 CEST | Press release
Circus SE (WKN: A2YN35 / ISIN: DE000A2YN355 / XETRA: CA1), today announces the commencement of live operations of its robotic-based troop supply technology with the 3rd Army Corps of the Ukrainian Ground Forces in the Kyiv area – marking the first ever use of autonomous meal supply systems within an active conflict environment. Ahead of deployment, Circus received regulatory certification from the State Service of Ukraine for Food Safety and Consumer Protection. This certification confirms compliance with all applicable health, quality, and safety standards required to import the company's technology into Ukraine, and clears the path for operational use at scale. Soldiers are supplied using Circus's full technology stack, comprising the hardware system, AI-controlled software, and proprietary ingredient infrastructure that underpins autonomous meal production in military environments. The deployment marks Circus's entry into the Ukrainian market and the operational commencement of the
Fourthline and Veridas Join Forces to Fight Identity Fraud with a Global Identity Platform16.7.2026 11:21:00 CEST | Press release
Founded in Europe, now with global reach: backed by European investors and bringing bank-grade European compliance standards to markets worldwide Customer Value: A streamlined, end-to-end user experience that protects identity across the entire customer lifetime and helps customers grow revenue safely and compliantly. The Expected Result:Fourthline and Veridas are joining forces to create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US. One trusted partner for end-to-end KYC, AML, and Identity compliance. Terms of Deal: Following completion of the merger, Veridas shareholders (including BBVA) will continue as shareholders in the combination, and the transaction will be partially funded by existing Fourthline investor Finch Capital and new investors including Rabo Investments, the captive investment arm of Rabobank. Expected close is in the second half of 2026, pending c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom